Surface Oncology, Inc.

Coherus BioSciences has been transitioning from a focus on biosimilars to developing and commercializing its own immuno-oncology therapies – led by anti-PD-1 agent Loqtorzi (toripalimab-tpzi) – and it

Clasp Therapeutics is developing next-generation T-cell engagers with the aim of developing off-the-shelf immuno-oncology therapeutics that have precise tumor targeting with limited on-target, off-tu

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Coherus Ends TIGIT Pact With Junshi Des

Having successfully landed their anti-PD-1 Loqtorzi (toripalimab) in the US, Shanghai Junshi Biosciences Co., Ltd. and Coherus BioSciences, Inc. are set to jump-start a partnership bonanza for pot